Bayer AG opened its first Cell Therapy Launch Facility in Berkeley, CA to create the capacity to bring cell therapies to patients on a global scale. The $250 million, 100,000-sq.-ft. facility will supply the material required for late-stage clinical trials and potential commercial launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in development for Parkinson’s disease. It also includes space for a second module of production suites to support ad...